{
  "main_header": {
    "sid": 1003871,
    "name": "Cell Point",
    "stock_name": "Cell Point",
    "full_name": "Cell Point (India) Ltd",
    "name_url": "stocks-analysis/cell-point",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "17.40",
    "chg": 0.25,
    "chgp": "1.46%",
    "dir": 1,
    "prev_price": "17.15",
    "mcapval": "32.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "CELLPOINT",
    "ind_name": "Retailing",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE0O0001013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 2400,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cell-point-1003871-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Cell Point falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-cell-point-fallingrising-3727171",
        "imagepath": "",
        "date": "2025-11-25 01:46:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Persistent Downtrend Against Market Benchmarks</strong></p>\n<p>Cell Point’s recent price trajectory has been notably weak when compared to the broader Sensex benchmark. Over the past week, the stock has fallen by 4.49%, significantly underperforming the Sensex’s marginal decline of 0.21%. This negative trend extends over longer periods as well, with the stock down 4.23% in the last month while the Sensex gained 0.64%. More strikingly, the year-to-date performance shows Cell Point plunging 36.45%, in stark contrast to the Sensex’s robust 9.79% gain. Over the last year, the stock has declined by 40.04%, whereas the Sensex has appreciated by 8.58%. These figures highlight a sustained period of underperformance, signalling structural or sector-specific headwinds impacting investor sentiment towa..."
      },
      {
        "title": "Why is Cell Point falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-cell-point-fallingrising-3716595",
        "imagepath": "",
        "date": "2025-11-20 00:16:29",
        "description": "As of 19-Nov, Cell Point (India) Ltd is experiencing a decline in its stock price, currently at 17.25, which reflects a decrease of 0.5 or 2.82%. The stock has underperformed its sector by 2.56% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the delivery volume has dropped significantly, with a 26.47% decrease compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has seen a return of -6.50%, and year-to-date, it has declined by 35.51%, which is substantially worse than the Sensex's positive return of 10.18% during the same period.\n\nIn the broader market context, while the Sensex has shown a slight increase of 0.68% over the past week and a notable gain of 10.18% year-to-date, Cell Point's performance starkly contrasts this trend, highlighting its struggles in the current market environment. The signi..."
      },
      {
        "title": "Is Cell Point overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cell-point-overvalued-or-undervalued-3706114",
        "imagepath": "",
        "date": "2025-11-17 08:11:32",
        "description": "As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all suggesting that the stock is priced significantly higher than its earnings potential.\n\nIn comparison to its peers, Cell Point's valuation appears particularly high when contrasted with PTC India, which has a PE ratio of 7.52 and is rated as very attractive, and Optiemus Infra, rated as fair with a PE of 75.09. This stark difference in valuation metrics underscores the overvaluation of Cell Point. Additionally, while the stock has shown a recent one-week return of 8.33% compared to the Sensex's 1.64%, its year-to-date performance is concerning, with a decline of 27.1% against a 9.58% rise in t..."
      },
      {
        "title": "Is Cell Point overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cell-point-overvalued-or-undervalued-3705476",
        "imagepath": "",
        "date": "2025-11-16 08:11:09",
        "description": "As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30. These ratios suggest that Cell Point is trading at a significant premium compared to its earnings and cash flow metrics.\n\nIn comparison to its peers, Cell Point's valuation stands out starkly; for instance, PTC India, which is deemed very attractive, has a PE ratio of just 7.52, while Elitecon International is categorized as very expensive with a PE of 309.88. This stark contrast highlights Cell Point's overvaluation in the retailing sector. Additionally, despite a recent uptick in stock price, the year-to-date return of -27.1% significantly underperforms the Sensex's 9.58% return, further reinforcing the notion that Cell Point may not be a sound i..."
      },
      {
        "title": "Is Cell Point overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cell-point-overvalued-or-undervalued-3704681",
        "imagepath": "",
        "date": "2025-11-15 08:11:04",
        "description": "As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all of which suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.\n\nIn comparison to peers, Cell Point's PE ratio significantly exceeds that of PTC India, which stands at 7.52, and even Elitecon International, which is at 309.88, indicating that Cell Point is priced much higher relative to its earnings potential. Additionally, while Cell Point's price has recently seen a 8.33% increase over the past week, it has underperformed the Sensex with a year-to-date decline of 27.1% compared to the Sensex's gain of 9.58%. This further reinforces the notion that Cell Poi..."
      },
      {
        "title": "Why is Cell Point falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-cell-point-fallingrising-3699932",
        "imagepath": "",
        "date": "2025-11-13 23:55:57",
        "description": "As of 13-Nov, Cell Point (India) Ltd is experiencing a price increase, with its current price at 18.65, reflecting a change of 0.2 or 1.08% upward. The stock has outperformed its sector today by 6.41%, and it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its recent performance. However, there has been a notable decline in investor participation, with delivery volume dropping by 61.54% against the 5-day average, which could suggest a decrease in trading interest. Additionally, the stock's year-to-date performance shows a significant decline of 30.28%, and over the past year, it has fallen by 37.73%, indicating long-term challenges despite the recent uptick.\n\nIn the broader market context, Cell Point's short-term return of 2.75% over the past week has outpaced the Sensex, which increased by 1.45% during the same period. However, the stock's pe..."
      },
      {
        "title": "How has been the historical performance of Cell Point?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-cell-point-3695753",
        "imagepath": "",
        "date": "2025-11-13 00:38:19",
        "description": "Answer:\nThe historical performance of Cell Point shows a steady increase in net sales over the years, reaching 324.71 Cr in March 2025, up from 321.23 Cr in March 2024, and significantly higher than 295.67 Cr in March 2023. The total operating income mirrored this trend, with a rise to 324.71 Cr in March 2025 from 321.23 Cr in the previous year. However, the operating profit (PBDIT) has seen fluctuations, peaking at 19.34 Cr in March 2023 before declining to 8.88 Cr in March 2025. Profit before tax also experienced a decline, with 2.81 Cr reported in March 2025 compared to 9.87 Cr in March 2023. Profit after tax followed a similar pattern, increasing to 2.26 Cr in March 2025 from 1.69 Cr in March 2024 but down from 6.73 Cr in March 2023. \n\nIn terms of assets and liabilities, total assets grew to 137.69 Cr in March 2025 from 133.10 Cr in March 2024, with total liabilities also increasing to 137.69 Cr from 13..."
      },
      {
        "title": "Is Cell Point overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cell-point-overvalued-or-undervalued-3678115",
        "imagepath": "",
        "date": "2025-11-07 08:12:44",
        "description": "As of 6 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market position. The company is currently overvalued based on its high PE ratio of 91.67, which significantly exceeds the industry average, and an EV to EBITDA ratio of 9.92, suggesting that investors are paying a premium for its earnings before interest, taxes, depreciation, and amortization. Additionally, the return on capital employed (ROCE) stands at a mere 3.63%, reflecting inefficiencies in generating returns from its capital.\n\nIn comparison to its peers, Cell Point's valuation metrics are starkly higher; for instance, Elitecon International has a PE ratio of 392.28, while PTC India, considered very attractive, has a PE of just 7.83. This stark contrast highlights Cell Point's overvaluation in the retailing sector. Furthermore, the company's stock has underperforme..."
      },
      {
        "title": "Is Cell Point overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cell-point-overvalued-or-undervalued-3668757",
        "imagepath": "",
        "date": "2025-11-04 08:09:23",
        "description": "As of 3 November 2025, the valuation grade for Cell Point has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently considered fairly valued. Key ratios include a PE ratio of 90.91, an EV to EBITDA of 9.88, and a Price to Book Value of 0.45, which suggests that while the earnings multiple is high, the asset valuation is relatively low.\n\nIn comparison to its peers, Cell Point's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 358.31, and PTC India, which is very attractive with a PE ratio of 7.99. The significant disparity in PE ratios highlights Cell Point's relative valuation position within the retailing industry. Notably, the stock has underperformed against the Sensex over the past year, with a return of -44.62% compared to the Sensex's 6.00%, reinforcing the notion that the stock may ha..."
      }
    ],
    "total": 297,
    "sid": "1003871",
    "stock_news_url": "https://www.marketsmojo.com/news/cell-point-india-1003871"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "08 Dec 2025"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cell Point (India) Ltd has declared <strong>2%</strong> dividend, ex-date: 19 Sep 24",
          "dt": "2024-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Cell Point falling/rising?

2025-11-25 01:46:54

Persistent Downtrend Against Market Benchmarks

Cell Point’s recent price trajectory has been notably weak when compared to the broader Sensex benchmark. Over the past week, the stock has fallen by 4.49%, significantly underperforming the Sensex’s marginal decline of 0.21%. This negative trend extends over longer periods as well, with the stock down 4.23% in the last month while the Sensex gained 0.64%. More strikingly, the year-to-date performance shows Cell Point plunging 36.45%, in stark contrast to the Sensex’s robust 9.79% gain. Over the last year, the stock has declined by 40.04%, whereas the Sensex has appreciated by 8.58%. These figures highlight a sustained period of underperformance, signalling structural or sector-specific headwinds impacting investor sentiment towa...

Read More

Why is Cell Point falling/rising?

2025-11-20 00:16:29

As of 19-Nov, Cell Point (India) Ltd is experiencing a decline in its stock price, currently at 17.25, which reflects a decrease of 0.5 or 2.82%. The stock has underperformed its sector by 2.56% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the delivery volume has dropped significantly, with a 26.47% decrease compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has seen a return of -6.50%, and year-to-date, it has declined by 35.51%, which is substantially worse than the Sensex's positive return of 10.18% during the same period. In the broader market context, while the Sensex has shown a slight increase of 0.68% over the past week and a notable gain of 10.18% year-to-date, Cell Point's performance starkly contrasts this trend, highlighting its struggles in the current market environment. The signi...

Read More

Is Cell Point overvalued or undervalued?

2025-11-17 08:11:32

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all suggesting that the stock is priced significantly higher than its earnings potential. In comparison to its peers, Cell Point's valuation appears particularly high when contrasted with PTC India, which has a PE ratio of 7.52 and is rated as very attractive, and Optiemus Infra, rated as fair with a PE of 75.09. This stark difference in valuation metrics underscores the overvaluation of Cell Point. Additionally, while the stock has shown a recent one-week return of 8.33% compared to the Sensex's 1.64%, its year-to-date performance is concerning, with a decline of 27.1% against a 9.58% rise in t...

Read More

Is Cell Point overvalued or undervalued?

2025-11-16 08:11:09

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30. These ratios suggest that Cell Point is trading at a significant premium compared to its earnings and cash flow metrics. In comparison to its peers, Cell Point's valuation stands out starkly; for instance, PTC India, which is deemed very attractive, has a PE ratio of just 7.52, while Elitecon International is categorized as very expensive with a PE of 309.88. This stark contrast highlights Cell Point's overvaluation in the retailing sector. Additionally, despite a recent uptick in stock price, the year-to-date return of -27.1% significantly underperforms the Sensex's 9.58% return, further reinforcing the notion that Cell Point may not be a sound i...

Read More

Is Cell Point overvalued or undervalued?

2025-11-15 08:11:04

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all of which suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities. In comparison to peers, Cell Point's PE ratio significantly exceeds that of PTC India, which stands at 7.52, and even Elitecon International, which is at 309.88, indicating that Cell Point is priced much higher relative to its earnings potential. Additionally, while Cell Point's price has recently seen a 8.33% increase over the past week, it has underperformed the Sensex with a year-to-date decline of 27.1% compared to the Sensex's gain of 9.58%. This further reinforces the notion that Cell Poi...

Read More

Why is Cell Point falling/rising?

2025-11-13 23:55:57

As of 13-Nov, Cell Point (India) Ltd is experiencing a price increase, with its current price at 18.65, reflecting a change of 0.2 or 1.08% upward. The stock has outperformed its sector today by 6.41%, and it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its recent performance. However, there has been a notable decline in investor participation, with delivery volume dropping by 61.54% against the 5-day average, which could suggest a decrease in trading interest. Additionally, the stock's year-to-date performance shows a significant decline of 30.28%, and over the past year, it has fallen by 37.73%, indicating long-term challenges despite the recent uptick. In the broader market context, Cell Point's short-term return of 2.75% over the past week has outpaced the Sensex, which increased by 1.45% during the same period. However, the stock's pe...

Read More

How has been the historical performance of Cell Point?

2025-11-13 00:38:19

Answer: The historical performance of Cell Point shows a steady increase in net sales over the years, reaching 324.71 Cr in March 2025, up from 321.23 Cr in March 2024, and significantly higher than 295.67 Cr in March 2023. The total operating income mirrored this trend, with a rise to 324.71 Cr in March 2025 from 321.23 Cr in the previous year. However, the operating profit (PBDIT) has seen fluctuations, peaking at 19.34 Cr in March 2023 before declining to 8.88 Cr in March 2025. Profit before tax also experienced a decline, with 2.81 Cr reported in March 2025 compared to 9.87 Cr in March 2023. Profit after tax followed a similar pattern, increasing to 2.26 Cr in March 2025 from 1.69 Cr in March 2024 but down from 6.73 Cr in March 2023. In terms of assets and liabilities, total assets grew to 137.69 Cr in March 2025 from 133.10 Cr in March 2024, with total liabilities also increasing to 137.69 Cr from 13...

Read More

Is Cell Point overvalued or undervalued?

2025-11-07 08:12:44

As of 6 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market position. The company is currently overvalued based on its high PE ratio of 91.67, which significantly exceeds the industry average, and an EV to EBITDA ratio of 9.92, suggesting that investors are paying a premium for its earnings before interest, taxes, depreciation, and amortization. Additionally, the return on capital employed (ROCE) stands at a mere 3.63%, reflecting inefficiencies in generating returns from its capital. In comparison to its peers, Cell Point's valuation metrics are starkly higher; for instance, Elitecon International has a PE ratio of 392.28, while PTC India, considered very attractive, has a PE of just 7.83. This stark contrast highlights Cell Point's overvaluation in the retailing sector. Furthermore, the company's stock has underperforme...

Read More

Is Cell Point overvalued or undervalued?

2025-11-04 08:09:23

As of 3 November 2025, the valuation grade for Cell Point has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently considered fairly valued. Key ratios include a PE ratio of 90.91, an EV to EBITDA of 9.88, and a Price to Book Value of 0.45, which suggests that while the earnings multiple is high, the asset valuation is relatively low. In comparison to its peers, Cell Point's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 358.31, and PTC India, which is very attractive with a PE ratio of 7.99. The significant disparity in PE ratios highlights Cell Point's relative valuation position within the retailing industry. Notably, the stock has underperformed against the Sensex over the past year, with a return of -44.62% compared to the Sensex's 6.00%, reinforcing the notion that the stock may ha...

Read More

View All News